Research abstract
Each year, millions of Americans receive evidence-based psychotherapies (EBPs) such as cognitive
behavioral therapy (CBT) for the treatment of mental and behavioral health problems. Yet, at present, there is
no scalable method for evaluating the quality of psychotherapy services. In research settings, human-based
behavioral coding methods are used, but these are time consuming, costly, and rarely used in real-world
clinical settings. Thus, EBP quality and effectiveness is unmeasured and unknown. The current, fast-track
STTR proposal will develop and evaluate an AI-based software system (LyssnCBT) that will automatically
estimate CBT fidelity from an audio recording of a CBT session. Importantly, the current work builds from
Lyssn’s previous, successful work in developing an automated system for evaluating motivational interviewing
(MI), and previous research showing that AI algorithms can accurately estimate CBT fidelity.Lyssn.io, Inc., (“Lyssn”) is a start-up developing AI-based technologies to support training, supervision,
and quality assurance of evidence-based counseling. Our goal is to develop innovative health technology
solutions that are objective, scalable, and cost efficient. Lyssn offers a HIPAA-compliant, cloud-based platform
for secure recording, sharing, and reviewing of therapy sessions, which includes AI-generated metrics for MI.
The proposed LyssnCBT tool will build from and be integrated into this core platform. Lyssn is partnering with
Dr. Torrey Creed and the Penn Collaborative, which has a 14+ year track record of gold-standard CBT training
and supervision, including more than 100 community agencies with almost 900 providers. The expertise,
relationships, and amassed data -- more than 8,000 recorded sessions and more than 3,000 rated for CBT
fidelity -- form the clinical foundation for the current research.Phase I will work from an existing AI-CBT prototype to develop LyssnCBT. Core activities include
user-centered design focus groups and interviews with community mental health (CMH) therapists,
supervisors, and administrators, which will inform the design and development of LyssnCBT. LyssnCBT will be
evaluated for usability and implementation readiness in a final stage of Phase I. Phase II will conduct a
field-based usability trial and a stepped-wedge, hybrid implementation-effectiveness randomized trial (N =
1,850 CMH clients) to evaluate the effectiveness of LyssnCBT to improve therapist CBT skills and client
outcomes, and to reduce client drop-out. Analyses will also examine the hypothesized mechanism of action
underlying LyssnCBT.The research is strongly aligned with NIMH’s 2020 Strategic Plan and its emphasis on a computational
approach to scaling up treatment delivery and monitoring. Successful execution will provide automated,
scalable CBT fidelity feedback for the first time ever, supporting high-quality training, supervision, and quality
assurance, and providing a core technology foundation that could support a range of EBPs in the future.PROJECT NARRATIVE
Evidence-based psychotherapies such as cognitive-behavioral therapy (CBT) are increasingly emphasized in
professional practice guidelines, taught in training programs, sought out by consumers, and valued by payers.
Yet, at present, there is no scalable method for evaluating CBT fidelity to support training, supervision, and
quality assurance in community practice settings. The current study will develop and evaluate a clinical
support software tool (LyssnCBT) that uses speech signal processing and machine learning to automate CBT
fidelity and support high-quality CBT supervision and service delivery in community settings.
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Verified by an exact topic code match. This is not a text-similarity match.
10 SBIR/STTR records share this UEI (2018–2024). Reported award amounts total $10,409,021. Reported amounts are not federal obligations.